Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease

Nature

Volumn 543, Issue 7643, 2017, Pages 108-112

  Pandey, Manoj K ^a   Burrow, Thomas A ^a   Rani, Reena ^a   Martin, Lisa J ^a   Witte, David ^a   Setchell, Kenneth D ^a   McKay, Mary A ^a   Magnusen, Albert F ^a   Zhang, Wujuan ^a   Liou, Benjamin ^a   Köhl, Jörg ^a,b   Grabowski, Gregory A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD40 LIGAND; CERAMIDE GLUCOSYLTRANSFERASE; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; FC RECEPTOR; GAMMA INTERFERON; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; INTERLEUKIN 17F; C5AR1 PROTEIN, MOUSE; COMPLEMENT; CYTOKINE; GLUCOSYLTRANSFERASE;

AMINO ACID; ANATOMY; ANTIBODY; BONE; CANCER; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; ENZYME ACTIVITY; MUTATION; NERVOUS SYSTEM DISORDER; PROTEIN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GAUCHER DISEASE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; INFLAMMATION; LIPID STORAGE; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE ACTIVATION; U-937 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOLOGY; DEFICIENCY; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT C5A; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MICE; RECEPTOR, ANAPHYLATOXIN C5A; T-LYMPHOCYTES;

EID: 85014543831     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21368     Document Type: Article

References (25)

1. Pandey, M. K. et al. Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol. Genet. Metab. 111, 163-171 (2014).
2. van Dussen, L., Biegstraaten, M., Hollak, C. E. & Dijkgraaf, M. G. Costeffectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J. Rare Dis. 9, 51 (2014).
3. Aflaki, E. et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 15, 77-88 (2016).
4. Gervas-Arruga, J. et al. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease. PLoS One 10, e0126153 (2015).
5. Mistry, P. K., Taddei, T., vom Dahl, S. & Rosenbloom, B. E. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit. Rev. Oncog. 18, 235-246 (2013).
6. Bultron, G. et al. The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167-173 (2010).
7. Xu, Y. H., Quinn, B., Witte, D. & Grabowski, G. A. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 163, 2093-2101 (2003).
8. Kolev, M., Le Friec, G. & Kemper, C. Complement - tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811-820 (2014).
9. Klos, A., Wende, E., Wareham, K. J. & Monk, P. N. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65, 500-543 (2013).
10. Strainic, M. G. et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28, 425-435 (2008).
11. Weaver, D. J., Jr et al. C5a receptor-deficient dendritic cells promote induction of TREG and TH17 cells. Eur. J. Immunol. 40, 710-721 (2010).
12. Arbore, G. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 352, aad1210 (2016).
13. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563-604 (2013).
14. Otto, M. et al. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279, 142-151 (2004).
15. Nair, S. et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N. Engl. J. Med. 374, 555-561 (2016).
16. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
17. Syed, S. N. et al. Both Fcγ RIV and Fcγ RIII are essential receptors mediating type II and type III autoimmune responses via FcRγ-LAT-dependent generation of C5a. Eur. J. Immunol. 39, 3343-3356 (2009).
18. Boot, R. G. et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103, 33-39 (2004).
19. Pandey, M. K. & Grabowski, G. A. Immunological cells and functions in Gaucher disease. Crit. Rev. Oncog. 18, 197-220 (2013).
20. Cluzeau, C. V. et al. Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1. Hum. Mol. Genet. 21, 3632-3646 (2012).
21. Kanfer, J. N., Legler, G., Sullivan, J., Raghavan, S. S. & Mumford, R. A. The Gaucher mouse. Biochem. Biophys. Res. Commun. 67, 85-90 (1975).
22. Pandey, M. K., Rani, R., Zhang, W., Setchell, K. & Grabowski, G. A. Immunological cell type characterization and TH1-TH17 cytokine production in a mouse model of Gaucher disease. Mol. Genet. Metab. 106, 310-322 (2012).
23. Xu, Y. H. et al. Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid ß-glucosidase residual activity levels. Mol Genet. Metab. 94, 190-203 (2008).
24. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protocols 3, 1101-1108 (2008).
25. Sun, Y. et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum. Mol. Genet. 19, 1088-1097 (2010).